GILD GILEAD SCIENCES, INC.
What matters nowUpdated 7 h ago
- The most recent approval is Bixlenvo, a once-daily single-tablet HIV regimen of bictegravir and lenacapavir, cleared by the FDA on August 27, 2026 for adults who are virologically suppressed; the release gives no launch date or price 1.
- GILD trades at $148.80 on the pooled 24/7 venue price, down 1.23% from the $150.65 previous close. Sharp moves came on August 18 (+3.82%), September 8 (-2.88%) and October 9 (+3.27%).
- Q2 2026 revenue rose 10% to $7.8 billion, led by HIV medicines, Trodelvy and Livdelzi; the GAAP loss of $8.45 per diluted share reflected about $9.08 per share of acquired in-process R&D tied to the Arcellx, Tubulis and Ouro Medicines deals, and cash fell to $3.2 billion from $10.6 billion at the end of 2025 2.
- Over the twelve months to June 30, 2026, revenue was $30.5 billion and free cash flow $12.9 billion, a 7.0% free cash flow yield at a $184.7 billion market cap. In the last 180 days insiders filed 18 planned sales worth $25.7 million and no purchases.
- Gilead reports third-quarter 2026 results on an estimated October 29, 2026, not yet confirmed. The FDA action date for anito-cel is December 23, 2026, and the FDA action date for once-weekly oral Yeztugo is February 2, 2027 3.
Gilead Sciences newsroom · Aug 27
SEC Form 8-K, Exhibit 99.1 (Gilead) · Aug 4
EATG (reprint of Gilead press release) · Jun 15
Valuation & fundamentalsFull financials →
TTM through 2026-06-30 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price. Quarterly statements →
Every venue
| Venue | Price | vs pool | 24h vol | Open int. | Funding 8h |
|---|---|---|---|---|---|
| bybit perp GILDUSDT · just now | 147.92 | +0.27% | $2.4M | $32.4K | 0.0000% |
| bitget perp GILDUSDT · just now | 147.94 | +0.29% | $23.7K | $13.7K | 0.0000% |
Pooled price = volume-weighted median of venues within 2% of each other. Venue markets for stocks, indices and gold are 24/7 perpetual contracts; they track but are not the official exchange price.
Open interest, 120 days
US$ millions, all venues
Funding, 120 days
Annualised %, OI-weighted. Positive: longs pay shorts.
NewsAll news →
CEO Daniel O'Day sells 15,000 Gilead shares at about $147.90 on October 1
Chairman and CEO Daniel O'Day sold 15,000 Gilead shares on October 1, 2026, in two blocks: 12,000 shares at about $147.72 and 3,000 at about $148.63.
Gilead widens royalty-free lenacapavir licences to cover once-yearly HIV prevention
Gilead expanded six existing royalty-free voluntary licences for lenacapavir to cover the investigational once-yearly injection for HIV prevention, across 120 high-incidence countries, mostly low- and lower-middle-income.
CEO Daniel O'Day sells 15,000 Gilead shares at about $148.64
Chairman and CEO Daniel O'Day sold 15,000 Gilead shares on September 1, 2026, in three blocks priced from $146.94 to $149.94, a weighted average of about $148.64.
FDA approves Bixlenvo, Gilead's once-daily bictegravir and lenacapavir HIV pill
The FDA approved Bixlenvo (bictegravir 75 mg and lenacapavir 50 mg), a once-daily single-tablet HIV regimen for adults who are virologically suppressed and can replace their current regimen.
Gilead Q2 2026 revenue rises 10% to $7.8 billion; GAAP loss on acquired R&D charges
Gilead reported second-quarter 2026 total revenue of $7,803 million, up 10% from a year earlier, led by HIV medicines, Trodelvy and Livdelzi.
CEO Daniel O'Day sells 15,000 Gilead shares under a 10b5-1 plan
Chairman and CEO Daniel O'Day sold 15,000 Gilead shares on August 3, 2026, in three open-market blocks priced from about $129.17 to $131.47, a weighted average of about $130.31.
EU regulator backs Trodelvy plus Keytruda for first-line PD-L1-positive breast cancer
The EMA's CHMP recommended Trodelvy combined with Keytruda for adults with unresectable or metastatic triple-negative breast cancer who have not had prior systemic therapy for metastatic disease and whose tumors are PD-L1 positive (CPS 10 or higher).
Gilead and Merck report Week 48 data for once-weekly oral HIV pill islatravir/lenacapavir
Gilead and Merck reported Week 48 Phase 3 results for once-weekly islatravir and lenacapavir, meeting the primary endpoint in both ISLEND trials.
FDA approves Trodelvy for first-line metastatic triple-negative breast cancer
The FDA approved Trodelvy as a first-line treatment for metastatic triple-negative breast cancer.
FDA accepts application for once-weekly oral Yeztugo, PDUFA date February 2, 2027
The FDA accepted Gilead's supplemental application for a once-weekly oral 300 mg lenacapavir tablet for HIV prevention, with a PDUFA action date of February 2, 2027.
Gilead and Merck report positive Phase 3 ISLEND-1 and ISLEND-2 results for once-weekly HIV pill
Gilead and Merck said both Phase 3 ISLEND trials of once-weekly oral islatravir plus lenacapavir met their Week 48 primary endpoint.
Merck and Gilead stop Phase 3 KEYNOTE-D46/EVOKE-03 lung cancer study
Merck and Gilead said an independent Data Monitoring Committee recommended stopping the Phase 3 trial of Trodelvy plus Keytruda in previously untreated PD-L1-high non-small cell lung cancer.
Livdelzi Phase 3 IDEAL trial meets primary endpoint in PBC patients with elevated ALP
Gilead said the Phase 3 IDEAL trial of Livdelzi (seladelpar) met its primary endpoint, a composite of alkaline phosphatase at or below 1.0 times the upper limit of normal with a 15% or greater drop from baseline at Week 52.
FDA grants accelerated approval to Hepcludex, first US treatment for chronic hepatitis delta
The FDA granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus infection who have no cirrhosis or compensated cirrhosis.
EMA's CHMP backs Trodelvy monotherapy for first-line triple-negative breast cancer in Europe
The EMA's CHMP adopted a positive opinion recommending Trodelvy as a monotherapy for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitors.